Journal
ANNALS OF HEMATOLOGY
Volume 95, Issue 12, Pages 1931-1942Publisher
SPRINGER
DOI: 10.1007/s00277-016-2810-z
Keywords
Acute myeloid leukemia; All-trans retinoic acid; Nucleophosmin-1
Categories
Funding
- German Bundesministerium fur Bildung und Forschung (BMBF) [01GI9981, 01KG0605]
- German Research Foundation [DFG FI405/5-1, 1339/3-1, BU 1339/5-1, SFB 1074 B3]
- Deutsche Jose Carreras Leukamie-Stiftung [DJCLS H 05/02]
- Pfizer
Ask authors/readers for more resources
The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA therapy in younger adult patients (18-60 years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45 mg/m(2), days 6-8; 15 mg/m(2), days 9-21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred patients were randomized (556, STANDARD; 544, ATRA) with 38 patients treated vice versa. Median follow-up for survival was 5.2 years. ITT analyses revealed no difference between ATRA and STANDARD for the total cohort and for the subset of NPM1-mutated AML with respect to event-free (EFS; p = 0.93, p = 0.17) and overall survival (OS; p = 0.24 and p = 0.32, respectively). Pre-specified PP analyses revealed better EFS in NPM1-mutated AML (p = 0.05) and better OS in the total cohort (p = 0.03). Explorative subgroup analyses on an ITT basis revealed better OS (p = 0.05) in ATRA for genetic low-risk patients according to ELN recommendations. The clinical trial is registered at clinicaltrialsregister.eu (EudraCT Number: 2004-004321-95).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available